P-17

Acute cholinergic syndrome in a patient with Alzheimer's disease taking the prescribed dose of galantamine

Tomoki Hanazawa^{1, 5}, Yoshito Kamijo¹, Tomohiro Yoshizawa^{1, 2}, Yuji Fujita³, Kiyotaka Usui⁴ ¹Emergency Center and Poison Center, Saitama Medical University Hospital, Saitama, Japan; ²Department of Pharmacy, Saitama Medical University Hospital, Saitama, Japan; ³Department of Emergency, Iwate Medical University Hospital, Iwate, Japan; ⁴Department of Forensic Medicine, Tohoku University Graduate School of Medicine, Miyagi, Japan; ⁵Department of general internal medicine, Fujimi Hospital, Tokyo, Japan

Objective: We report a case of acute cholinergic syndrome caused by prescribed dose of galantamine.

Case report: An 87-year-old man with Alzheimer's disease taking 24 mg of galantamine (a 12-mg tablet twice a day at 8 a.m. and 8 p.m.) was transported to the Emergency Center and Poison Center when he was found to be unresponsive by his family. On admission, at about 8 a.m., he was drowsy with a consciousness level of E3V4M6 on the Glasgow Coma Scale and had miosis (diameters of both pupils, 1.5 mm), sinus bradycardia (54 beats/min), excessive salivation, nausea, and enhanced bowel sounds. Initial blood tests were unremarkable. Computed tomography of the brain revealed moderate brain atrophy. A provisional diagnosis of acute cholinergic syndrome caused by galantamine was made. He was treated with fluid infusion and recovered within 7 hours of hospital admission. Drug analysis using liquid chromatography–mass spectrometry revealed that the calculated maximum serum galantamine concentration during a dose interval at steady state (75.1 ng/mL) was not elevated and that the calculated elimination half-life (9.6 hours) was not prolonged. This suggests that acute cholinergic syndrome developed not due to poisoning, but as an adverse reaction.

Conclusion: Physicians should consider the possibility that galantamine taken at the prescribed dose can cause acute cholinergic syndrome.

